Home/Pipeline/Myosana Platform for DMD

Myosana Platform for DMD

Duchenne Muscular Dystrophy

Pre-clinicalActive

Key Facts

Indication

Duchenne Muscular Dystrophy

Phase

Pre-clinical

Status

Active

Company

Myosana Therapeutics

About Myosana Therapeutics

Myosana Therapeutics is an early-stage, privately held biotech focused on creating a transformative, non-viral gene delivery platform for genetic muscle diseases. The company has secured seed funding and strategic investments from patient advocacy groups to advance its lead programs. Its core strategy is to develop a targeted, muscle-specific delivery system that could expand the treatable disease landscape beyond the constraints of viral-based therapies.

View full company profile

Therapeutic Areas

Neuromuscular Diseases Cardiac Diseases

Other Duchenne Muscular Dystrophy Drugs

Drug	Company	Phase	Status
MyoPAXon	Myogenica	Phase 1	Active
DMD Gene Therapy	Kinea Bio	Pre-clinical	Active
NS-051/NCNP-04	NS Pharma	Phase 1/2	Active
UCT-MSC + Biomaterials	Vitti Labs	Phase 2	Active
PEPR-124 (RT-001)	Peptris Technologies Private	Phase 2-ready	Licensed to Revio Therapeutics
DMD Genetic Screening Panel	Nanodigmbio	Commercial	Active
KHR‑001	KAHR Medical	Preclinical	Active
PF-06939926	Pfizer	Phase 3	Active